Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19205561 | 1.00 | RORC (0.47) | RORCTRPV1NPC1RAB9AKMT2A | |
| SCHEMBL19205774 | 0.91 | GAA (0.48) | RORCTRPV1KMT2AMEN1MAPT | |
| SCHEMBL18447801 | 0.90 | NPC1 (0.51) | RORCTRPV1NPC1RAB9AKMT2A | |
| SCHEMBL19205793 | 0.90 | RORC (0.49) | RORCTRPV1KMT2AMEN1MAPT | |
| SCHEMBL18449588 | 0.85 | RORC (0.47) | RORCTRPV1KMT2AMEN1MAPT | |
| SCHEMBL18448350 | 0.83 | RORC (0.50) | RORCNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL18448279 | 0.83 | WNT3A (0.54) | RORCNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL19205654 | 0.83 | RAB9A (0.53) | RORCNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL19205592 | 0.83 | RAB9A (0.53) | RORCNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL19205766 | 0.83 | RORC (0.48) | RORCNPC1RAB9AMAPTNR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026050-B | Novel compounds as ROR gamma modulators | 格兰马克药品股份有限公司 | 2021-04-30 | — | — | CN | claimed |
| EP-3331863-B1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2020-03-11 | — | — | EP | claimed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | claimed |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-08-23 | — | — | US | claimed |
| US-9975887-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-05-22 | — | — | US | claimed |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-17 | — | — | US | claimed |
| US-10988467-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2021-04-27 | — | — | US | disclosed |
| EP-3686187-A1 | PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-3331863-B1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-08-23 | — | — | US | disclosed |
| US-9975887-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-05-22 | — | — | US | disclosed |
| US-9975887-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-05-22 | — | — | US | disclosed |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-17 | — | — | US | disclosed |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988467-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | RORC 3/4885TRPV1 623/4885NPC1 2924/4885 |
| US-10344024-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | RORC 3/4885TRPV1 623/4885NPC1 2924/4885 |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | RORC 3/4885TRPV1 569/4885NPC1 3074/4885 |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | RORC 3/4885TRPV1 305/4885NPC1 2220/4885 |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | RORC 3/4885TRPV1 569/4885NPC1 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.